UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to _____ Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or ...

Volition© 2021 May 2021 Corporate Presentation Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "antici ...

VolitionRx Limited (NYSE:VNRX) Q1 2021 Results Conference Call May 12, 2021 8:00 AM ET Company Participants Scott Powell - Executive Vice President of Investor Relations Cameron Reynolds - President and Chief Executive Officer Terig Hughes - Chief Financial Officer Conference Call Participants Kyle Mikson - Cantor Fitzgerald Bruce Jackson - Benchmark Company Jason McCarthy - Maxim Group Nathan Weinstein - Agesi Capital Operator Good morning, ladies and gentlemen. Thank you for standing by. Welcome to Voliti ...

Financial Performance - Total revenues for the three months ended March 31, 2021, were $25,530, compared to $544 for the same period in 2020, representing an increase of over 100%[145] - The net loss for the three months ended March 31, 2021, was $6,125,570, compared to a net loss of $5,859,339 for the same period in 2020, an increase of 5%[146] - The company's net loss for Q1 2021 was $6.1 million, an increase of approximately $0.2 million from a net loss of $5.9 million in Q1 2020[157] - The company achieved a revenue of $5 million for the quarter, representing a 15% increase compared to the previous quarter[186] - VolitionRx expects to provide updated earnings guidance, projecting a revenue increase of 10% for the next quarter[186] Revenue Sources - The main source of revenues during the three months ended March 31, 2021, was direct sales of the Nu.Q Vet Cancer Screening Test[147] Cash Flow and Financing - Net cash used in operating activities was $6.2 million for the three months ended March 31, 2021, compared to $4.8 million for the same period in 2020, an increase of 29%[135] - Net cash provided by financing activities was $20.2 million for the three months ended March 31, 2021, primarily due to $18.9 million from the issuance of common stock[137] - The company plans to secure additional grant funds and obtain equity or debt financing to sustain operations[132] - The company plans to seek additional capital through the sale of debt or equity securities as necessary[160] Operating Expenses - Total operating expenses increased to $6.1 million for the three months ended March 31, 2021, from $5.9 million for the same period in 2020, an increase of 4%[148] - Research and development expenses were $3,873,079 for the three months ended March 31, 2021, a slight decrease of 1% from $3,894,966 in the same period in 2020[146] - General and administrative expenses increased to $1.8 million in Q1 2021, up from $1.7 million in Q1 2020, primarily due to higher personnel and legal expenses[152] - Sales and marketing expenses rose to $0.4 million in Q1 2021, compared to $0.3 million in Q1 2020, driven by increased personnel costs[154] - Personnel expenses in research and development increased to $1.49 million in Q1 2021 from $1.27 million in Q1 2020[151] - Stock-based compensation in general and administrative expenses surged to $333,866 in Q1 2021 from $107,265 in Q1 2020[153] Internal Controls and Compliance - As of March 31, 2021, the company identified material weaknesses in internal controls over financial reporting and is implementing a remediation plan[168] - The company has not maintained sufficient internal controls in areas such as segregation of duties and oversight in IT[168] - The Audit Committee regularly meets with financial management and independent auditors to discuss internal accounting controls[168] - The company continues to evaluate and enhance its internal controls over financial reporting[171] - The company does not expect its disclosure controls and internal controls to prevent all errors and fraud[172] Market Strategy and Growth - VolitionRx is focusing on expanding its market presence in Europe, targeting a 30% increase in market share by the end of the fiscal year[186] - The company is investing in new product development, with a budget allocation of $2 million for research and innovation in the next quarter[186] - VolitionRx plans to enhance its technology platform, aiming for a 20% improvement in processing efficiency by Q3 2021[186] - The company has outlined a strategic goal to pursue potential acquisitions, with a target of identifying at least two candidates by the end of the year[186] - The company has initiated a new marketing strategy, aiming to increase brand awareness by 40% through digital channels[186] - VolitionRx is committed to improving customer engagement, with a goal of increasing customer satisfaction scores by 15% in the upcoming quarter[186] - The company has reported a successful pilot program for its new diagnostic product, with a 90% accuracy rate in initial tests[186] Risk Factors and Legal Proceedings - The company has substantial doubt about its ability to continue as a going concern without obtaining external financing[158] - The company has not experienced any material changes in risk factors affecting its business since the last annual report[177] - There are no material, existing or pending legal proceedings against the company[176] - There were no significant off-balance sheet arrangements that could materially affect the company's financial condition[159]

Volition© 2021 March 2021 Corporate Presentation Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anti ...

VolitionRx Limited (NYSE:VNRX) Q4 2020 Results Conference Call March 23, 2021 8:00 AM ET Company Participants Scott Powell - Investor Relations Cameron Reynolds - President and Chief Executive Officer Terig Hughes - Chief Financial Officer Dr. Jake Micallef - Chief Scientific Officer Conference Call Participants Kyle Mikson - Cantor Fitzgerald Jason McCarthy - Maxim Group Nathan Weinstein - Agesi Capital Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen, and thank you for standin ...

Volition© 2021 March 2021 Corporate Presentation Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [X] For the Fiscal Year Ended December 31, 2020 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [ ] For the transition period from _____ to ______ Commission File Number: 001-36833 VOLITIONRX LIMITED (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpor ...

VolitionRx Ltd. (NYSE:VNRX) Q3 2020 Earnings Conference Call November 13, 2020 8:30 AM ET Company Participants Scott Powell - EVP, IR Cameron Reynolds - President and CEO David Vanston - CFO Jason Terrell - Chief Medical Officer Conference Call Participants Jason McCarthy - Maxim Group Kyle Mikson - Cantor Fitzgerald Bruce Jackson - Benchmark Company Jason Kolbert - Dawson James Steven Ralston - Zacks Investment Research Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to ...

Volition© 2020 Corporate Presentation November 2020 Forward Looking Statements and Disclaimer Statements in this document may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "a ...